Guggenheim Downgrades Black Diamond Therapeutics on Silevertinib Concerns
Guggenheim lowers Black Diamond Therapeutics to Neutral, citing toxicity and durability concerns in silevertinib’s Phase 2 trial and risks to key 2026 catalysts.
/ 1665 items
#XY↓
Protara Therapeutics Shares Climb on Strong Phase 2 Trial Results for TARA-002
Protara Therapeutics stock jumped after positive Phase 2 interim results showed strong response rates for TARA-002 in non-muscle invasive bladder cancer patients.
MapLight Therapeutics Gains from Bristol Myers’ ADEPT-2 Study Update
MapLight Therapeutics sees upside as Bristol Myers continues ADEPT-2 Alzheimer’s psychosis trial despite site irregularities, with potential catalysts for 2026.
Capricor's DMD Therapy Shows Major Promise in Phase 3 Trial
Capricor's (CAPR) deramiocel cell therapy achieved significant skeletal and cardiac improvements in Duchenne muscular dystrophy patients, potentially reversing FDA rejection after July setback.
Morgan Stanley Shifts Outlook on Vertex and Regeneron
Morgan Stanley upgrades Vertex Pharmaceuticals on promising kidney pipeline progress and downgrades Regeneron due to balanced risk/reward and valuation concerns.
Analyst Bullish Momentum Builds Around Compass Therapeutics
Multiple analysts initiate bullish coverage on Compass Therapeutics (CMPX), highlighting promising data for lead drug tovecimig and strong pipeline potential.